Breaking News: Immix Biopharma’s Revolutionary CAR-T Treatment Shows Promise in U.S. Clinical Trial!
A Breakthrough in AL Amyloidosis Treatment: The Promise of NXC-201 Introduction Exciting news has emerged from Immix Biopharma, Inc., with the recent announcement of groundbreaking results from the NEXICART-2 U.S. study. All four patients treated with NXC-201 have shown remarkable progress, with disease markers normalized within just 30 days of dosing. What’s more, two of…